Abstract
Get full access to this article
View all access options for this article.
References
1.
Yoong
D
Naccarato
M
Gough
K
. Extensive bruising and elevated rivaroxaban plasma concentration in a patient receiving cobicistat-boosted elvitegravir [published online March 1 , 2017 ]. Ann Pharmacother . doi: 10.1177/1060028017702677 .
2.Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for use of antiretroviral agents in HIV-1 infected adults and adolescents . http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed April 18, 2017 .
3.
Gordon
LA
Kumar
P
Brooks
KM
et al
. Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-negative healthy volunteers . Circulation . 2016 ;134 :1909 -1911 .
4.British Columbia Centre for Excellence in HIV/AIDS . Therapeutic guidelines for antiretroviral (ARV) treatment of adult HIV infection . http://www.cfenet.ubc.ca/sites/default/files/uploads/Guidelines/bccfe-art-guidelines-Oct_14_2015.pdf. Accessed April 18, 2017 .
5.World Health Organization . Clinical guidelines: antiretroviral therapy . http://www.who.int/hiv/pub/arv/chapter4.pdf?ua=1. Accessed April 18, 2017 .
6.
Sebaaly
JC
Kelley
D.
A review of single-tablet regimens for the treatment of HIV-1 infection . Ann Pharmacother . 2017 ;51 :332 -344 .
7.
Durham
SH
Badowski
ME
Liedtke
MD
et al
. Acute care management of the HIV-infected patient: a report from the HIV practice and research network of the American college of clinical pharmacy . Pharmacotherapy . 2017 May;37 (5 ):611 -629 . doi:10.1002/phar.1921 .